TNF and T-cell non-Hodgkin lymphoma: A recent detailed analysis of 100 cases of T-cell non-Hodgkin’s lymphoma (NHL) reported to the US FDA disclosed that 68% of the cases involved exposure to both a TNF-alpha inhibitor and an immunomodulator.